QuickView for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=83E286E74EDD02FF9D8798CF638465E5;jsessionid=D7FFE99F12BF2E4EB7D38EBC69DA554B;jsessionid=36F903B008D559D25B0614918BC4DCE5;jsessionid=465606163BCE8F6E8A7CE02352D7D8E0;jsessionid=9EEF6C911AF1A5F08FED7386817B96CD;jsessionid=A659BD0D7A29FE1F5EBE0B96DF29FE90;jsessionid=24B02A5DA0CFD0696F7363C8FA430FB5;jsessionid=B6E90D9A5956A12A3638331287AEBE37;jsessionid=77D4B1FFA97AA2F39DA3B693708D8D07 (gene)

1. Biochemical characterization of mutants in chaperonin proteins CCT4 and CCT5 associated with heredit…
2. Role of CCT4/ErbB signaling in nephroblastoma: Implications for a biomarker of Wilms tumor.
3. Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair pro…
4. Transient Kinetic Analysis of ATP Hydrolysis by the CCT/TRiC Chaperonin.
5. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal sq…

There were no clinical trials for YDL143W;jsessionid=AF9A6F4065C670FDF1AB5408FD20ADBE;jsessionid=83E286E74EDD02FF9D8798CF638465E5;jsessionid=D7FFE99F12BF2E4EB7D38EBC69DA554B;jsessionid=36F903B008D559D25B0614918BC4DCE5;jsessionid=465606163BCE8F6E8A7CE02352D7D8E0;jsessionid=9EEF6C911AF1A5F08FED7386817B96CD;jsessionid=A659BD0D7A29FE1F5EBE0B96DF29FE90;jsessionid=24B02A5DA0CFD0696F7363C8FA430FB5;jsessionid=B6E90D9A5956A12A3638331287AEBE37;jsessionid=77D4B1FFA97AA2F39DA3B693708D8D07